Gangnam Severance Hospital
Seoul, South Korea
29 recruiting
Showing 1–20 of 47 trials
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled226 locationsNCT06790693
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled452 locationsNCT06531824
Recruiting
Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931
Recruiting
Phase 1
A Study of ZW191 in Participants With Solid Tumors
Advanced Solid Tumors
Zymeworks BC Inc.145 enrolled27 locationsNCT06555744
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled50 locationsNCT06787612
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
Arthritis, RheumatoidColitis Ulcerative
Eisai Korea Inc.2,040 enrolled64 locationsNCT06246123
Recruiting
Phase 3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Low Grade Serous Ovarian Cancer
Verastem, Inc.270 enrolled106 locationsNCT06072781
Recruiting
Not Applicable
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
NRG Oncology1,956 enrolled549 locationsNCT04251052
Recruiting
Observational Study for Left Main Disease Treatment
Coronary Artery Disease
Seung-Jung Park10,000 enrolled42 locationsNCT01341327
Recruiting
Study of the Natural History of FFR Guided Percutaneous Coronary Intervention
Coronary Artery Disease
Seung-Jung Park20,000 enrolled29 locationsNCT01366404
Recruiting
Phase 2
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Endometrial CancerPlatinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+8 more
MacroGenics60 enrolled16 locationsNCT06730347
Recruiting
Phase 4
MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
Acute Coronary Syndrome
CHA University490 enrolled9 locationsNCT06543082
Recruiting
Not Applicable
Nostril Side on Epistaxis
Nasotracheal Intubation
Seoul National University Hospital208 enrolled2 locationsNCT06605989
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc674 enrolled203 locationsNCT06757634